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Abstract
Background: The expression of vaccine antigens in lactic acid bacteria (LAB) is a safe and cost-
effective alternative to traditional expression systems. In this study, we investigated i) the
expression of Human papillomavirus type 16 (HPV-16) L1 major capsid protein in the model LAB
Lactococcus lactis and ii) the ability of the resulting recombinant strain to produce either capsomer-
or virus-like particles (VLPs).
Results and conclusion: HPV-16 L1 gene was cloned into two vectors, pCYT and pSEC,
designed for controlled intra- or extracellular heterologous expression in L. lactis, respectively. The
capacity of L. lactis harboring either pCYT:L1 or pSEC:L1 plasmid to accumulate L1 in the cytoplasm
and supernatant samples was confirmed by Western blot assays. Electron microscopy analysis
suggests that, L1 protein produced by recombinant lactococci can self-assemble into structures
morphologically similar to VLPs intracellularly. The presence of conformational epitopes on the L.
lactis-derived VLPs was confirmed by ELISA using an anti-HPV16 L1 capsid antigen antibody. Our
results support the feasibility of using recombinant food-grade LAB, such as L. lactis, for the
production of L1-based VLPs and open the possibility for the development of a new safe mucosal
vector for HPV-16 prophylactic vaccination.
Background
Human papillomavirus type 16 (HPV-16) infection is
closely associated with the development of cervical cancer
(CxCa) [1], the second cause of cancer-related deaths in
women worldwide (~250 000 annually) [2]. Therefore, a
prophylactic vaccine against HPV-16 is thus a priority to
prevent this type of cancer. HPV-16 L1 major capsid pro-
tein is able to self-assemble into virus-like particles (VLPs)
which are structures that are morphologically similar and
immunogenic as to native HPV [17]. Prophylactic vac-
cines based on highly purified VLPs were successfully used
in trials in women with a significant reduction observed in
the incidence of both HPV-16 infection and HPV-16
related CxCa [3], and now two vaccines, Gardasil and Cer-
varix, have been approved for use against this cancer. In
developing countries, where about 80% of CxCa occurs
[2], immunization programs would be more efficient and
economical if vaccines are temperature stable, required
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less doses to immunize and could be administered with-
out the need for specially trained personnel and instru-
ments (eg. needles).
Alternatively, mucosal vaccines (e.g. administered by oral,
intranasal, rectal or vaginal route) are more convenient
than systemic vaccines, because they are easier to admin-
ister, relatively cheap to produce and less invasive, an
especially important criteria when used with children and
immunosuppressed patients [5]. Furthermore, mucosal
vaccines can stimulate serum-IgG and mucosal-IgA Abs
(to neutralize toxins and viruses) and induce CTL activi-
ties [6].
Lactic acid bacteria (LAB) are non-pathogenic and non-
invasive Gram-positive bacteria considered as being
promising candidates for controlled and targeted admin-
istration of vaccine antigens to the mucosal immune sys-
tem [7-9]. Because of their long and safe association with
humans and their food such bacterial vectors represent a
good alternative to the use of classical attenuated patho-
genic bacterial carriers. Moreover, some LAB strains are
well known for their probiotic effect in humans [for a
review see Reference 9]. Previously, we reported HPV-16
E7 production in Lactococcus lactis, the model LAB [10-12].
Mucosal immunization with recombinant L. lactis
expressing E7 antigen and secreting biologically active IL-
12 induced an E7-specific response and displayed thera-
peutic effects against HPV-16-induced tumors in mice
[11,13]. This was the first study demonstrating the poten-
tial of recombinant non-pathogenic and non-invasive L.
lactis-based vaccines to help control HPV-related CxCa. An
alternative strategy to combat HPV-related cancer is the
prevention of infection with HPV. VLPs obtained by the
expression of HPV L1 major virion capsid protein using
recombinant vectors are good candidates for a prophylac-
tic HPV vaccine. Expression of HPV-16 L1 protein (for vac-
cine purposes) via heterologous LAB, including
Lactobacillus casei and L. lactis, has been previously shown
to generate VLPs [7,14,15]. Therefore, in this study, we
sought to determine whether L. lactis is able to produce
HPV-16 L1 protein using the NICE system [32] and
whether L1 protein produced by recombinant L. lactis is
able to self-assemble into either capsomers or VLPs.
Results and discussion
HPV-16 L1 production by Lactococcus lactis
The capacity of L. lactis to produce and secrete L1 protein
was examined using lactococci strains harbouring
pCYT:L1 and pSEC:L1 plasmids (Figure 1), respectively.
Non-induced and induced culture samples were exam-
ined by Western blot using HPV-16 L1-specific mono-
clonal antibodies. As shown in Figure 2A, no L1 signal was
detected in either cell or supernatant fractions of induced
cultures of the negative control L. lactis (pGK-). In the
absence of nisin, no L1 signal was detected in either L. lac-
tis (pCYT:L1) or L. lactis (pSEC:L1) strain, indicating that
NICE system allows tight control of gene expression.
Induced cultures of L. lactis (pCYT:L1) strain resulted in a
clear band at the expected size for native L1 (~58 kDa) was
observed in the cell fraction whereas no signal was
detected in the supernatant. Similar analysis of L. lactis
(pSEC:L1) resulted in a clear band in the cell fraction cor-
responding to SPUsp45-L1 precursor (pre-L1, ~60 kDa).
Unfortunately, since a major non-specific band (which
migrates at the expected size for native L1: ~58 kDa) reacts
with anti-L1 antibodies in supernatant samples, L1 secre-
tion cannot be determined. This non-specific band most
probably corresponds to Usp45, the predominant L. lactis-
secreted protein, and frequently detected by immunoblot-
ting when using protein G-horseradish peroxidase conju-
gate [10,16].
In order to better determine the secretion of L1 protein by
recombinant L. lactis (pSEC:L1) strain, we modified the
protocol of immunoblotting by using a higher dilution of
protein G-horseradish peroxidase conjugate (1:10,000)
and a higher concentration of HPV-16 L1-specific mono-
clonal antibody (0.5 μg/ml). We also used a higher dose
of nisin (ie. 10 ng/ml) for the induction of L1 expression.
As shown in Figure 2B, the modifications in the protocol
of immunoblotting and induction resulted in two bands,
a clear band in the cell fraction corresponding to SPUsp45-
L1 precursor (pre-L1, ~60 kDa), and a weak band in the
supernatant fraction corresponding to the secreted mature
L1 protein. Smaller-sized L1 products are also observed,
reflecting degradation by HtrA or ClpP proteases or
incomplete L1 synthesis at high expression levels (ie. 10
ng/ml of nisin). L1 secretion appears to be low, as about
only 5% of the protein is detected in the supernatant.
Production and secretion of HPV-16 L1 virus-like particles 
by L. lactis
To determine whether recombinant L1 protein undergoes
intracellular assembly into either capsomers or VLPs, TEM
analysis was carried out. As shown in Figure 3 (panel C
and D), structures morphologically similar to VLPs are
present in L. lactis (pCYT:L1) strain and have similar sizes
(30–50 nm in diameter) and morphologies as VLPs pro-
duced in other prokaryotic and eukaryotic systems (~55
nm) [14,15,17-20]. Surprisingly, VLPs are also present in
the cytoplasmic fraction of L. lactis (pSEC:L1) strain (Fig-
ure 3, panel E and F); however, most of these VLPs are
localized at the intracellular periphery of the bacterial
cells (arrowheads). This phenomenon could be due to the
self-assembly of small quantities of SPUsp45-L1 precursor
into VLPs, which are dealt with the L. lactis secretion
machinery via the translocon complex (early steps in the
secretion) [21], suggesting that the Usp45 signal peptide
(27 amino acids residues) does not interfere with intracel-BMC Research Notes 2009, 2:167 http://www.biomedcentral.com/1756-0500/2/167
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Schematic representation of pCYT:L1 (A) and pSEC:L1 (B) plasmids Figure 1
Schematic representation of pCYT:L1 (A) and pSEC:L1 (B) plasmids. A DNA fragment encoding L1 (see Materials 
and methods) was fused in frame with a DNA fragment containing the Usp45 signal peptide (pSEC:L1), derived from the pre-
dominant L. lactis-secreted protein. In pCYT:L1, the fragment encoding SPUsp45 is absent. In these plasmids, L1 expression is 
controlled by the nisin-inducible promoter (PnisA) and harbors the Usp45 ribosome binding site and the rho-independent trpA 
transcription terminator (ter) [10] for clone stability.
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lular assemblage of VLPs. Interestingly, some of these
VLPs appear to be secreted or released out into the exter-
nal medium (arrows) (Figure 3, panel G and H) by an
unknown mechanism. It may be possible that the nascent
secreted L1 protein undergoes self-assemble into VLPs
during later stages of the secretion process. No VLPs were
observed in negative control L. lactis (pGK-) (Figure 3,
panel A and B).
L. lactis-produced VLPs are recognized by a 
conformational antibody
In order to determine whether conformational epitopes
are retained and displayed on the L. lactis-produced VLPs,
an ELISA assay was performed using a monoclonal anti-
body that recognizes conformational epitopes present in
HPV-16 VLPs (see material and methods). Total protein
cell extracts from L. lactis strains were assayed using a con-
formational anti-HPV16 L1 antibody. As shown in Figure
4, cell extracts from L. lactis (pCYT:L1) and L. lactis
(pSEC:L1) strains resuspended in PBS pH 7.0 (assembled
VLPs) react with the anti-HPV16 L1 capsid antibody, indi-
cating that conformational epitopes are displayed on L.
lactis-derived VLPs. Note that the L. lactis (pCYT:L1) ELISA
signal is significantly higher with L. lactis (pSEC:L1)
strain. This could be explained in part by a higher quantity
of intracellular-VLPs in L. lactis (pCYT:L1) strain, as
observed by TEM analysis (Figure 3, panel C and D).
Indeed, ELISA results are based on cell lysates to coat the
plates and L. lactis (pSEC:L1) strain was designed for
secretion. Hence, it does not retain much VLPS and/or L1
protein intracellularly and most VLPs are secreted to the
external medium (Figure 3, panel G and H).
Expression of HPV-16 L1 protein by recombinant L. lactis Figure 2
Expression of HPV-16 L1 protein by recombinant L. 
lactis. A) L. lactis strains were grown and induced with 1 ng/
ml of nisin for 1 h. After centrifugation, non-induced (- nis) 
and induced (+ nis) culture samples were treated as 
described in materials and methods and L1 production and 
secretion analyzed by Western blot. L. lactis strain contains 
pCYT:L1 plasmid encoding for a cytoplasmic form of L1 and 
L. lactis strain contains pSEC:L1 encoding for the precursor 
preL1 (i.e. SPUsp45 fused to L1). B) L. lactis (pSEC:L1) strain 
was grown and induced with 10 ng/ml of nisin for 1 h. After 
centrifugation, induced (+ nis) culture samples were treated 
as described in results and discussion and L1 production and 
secretion analyzed by Western blot. Arrows indicate posi-
tions of L1 mature and precursor forms. Abbreviations: C, 
cell lysates; S, supernatant fraction; M, positions and sizes of 
molecular mass markers.
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Production and secretion of VLPs by L. lactis strains Figure 3
Production and secretion of VLPs by L. lactis strains. 
Electron micrographs of L. lactis (pGK-) (panel A and B), L. 
lactis (pCYT:L1) (panel C and D) and L. lactis (pSEC:L1) (panel 
E to H). The different strains were grown and prepared as 
described in material and methods. L. lactis-derived VLPs 
(arrows) have diameters ranging from ~30 to 50 nm (red 
bars = 50 nm). In L. lactis (pSEC:L1) strain, VLPs are localized 
at the intracellular periphery of the bacteria cells (arrow-
heads). Bars = 100 nm. Magnifications, A X50,000; B-G: 
X85,000; H: X140,000.
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Samples from the negative control L. lactis (pGK-) do not
react with the conformational antibody (Figure 4). As
expected, the anti-HPV16 L1 capsid antibody was not able
to recognize protein cell extracts from either L. lactis strain
resuspended in carbonate buffer pH 10.0 (disassembled
VLPs, data not shown).
Conclusion
Infections with HPV are closely related to the develop-
ment of CxCa [1]. For this reason, several development
strategies for prophylactic HPV vaccines have been
explored [17-20]. A potential vaccine candidate for the
production of such prophylactic vaccines is the HPV-16
L1 major capsid protein which can self-assemble into
VLPs. In fact, VLPs have been able to induce long lasting
protective immune responses, and a human systemic vac-
cine based on highly purified VLPs (derived from different
types of HPV: 6, 11, 16 and 18) is currently commercial-
ized [22]. This vaccine could in theory prevent ~70% of
CxCa cases [22,23]. Unfortunately, the high costs associ-
ated with its production and distribution hinders its wide-
spread application. A lower-cost alternative could be the
use of LAB for VLPs production instead. In fact, recom-
binant LAB could be used either as a cell factory for VLP
production or as a mucosal vaccine. Indeed, mucosal vac-
cines are more suited and convenient than systemic vac-
cines, because they are easier to administer and relatively
inexpensive to manufacture. In addition, since mucosal
surfaces are the primary site of interaction between an
organism and its environment and represent the major
portal of entry for pathogens (e.g. HPV-16), development
of effective mucosal vaccines is advantageous.
In this work, we used the model LAB, L. lactis, to produce
HPV-16 L1 protein and we demonstrated by Western blot
analysis that full-length L1 protein could be efficiently
expressed in L. lactis. We also demonstrated for the first
time that L. lactis-derived L1 protein can self-assemble
into structures morphologically similar to VLPs intracellu-
larly by TEM experiments. Most important, these VLPs dis-
play conformational epitopes as confirmed by ELISA
analysis. This is the first time that HPV-16 L1 protein is
produced in L. lactis using the NICE system [32]. This sys-
tem allows controlled gene expression by addition of
nisin, an antimicrobial peptide used as a natural preserv-
ative in the food industry, and more importantly, the level
of gene expression can be up-regulated more than 1000-
fold. Since, L. lactis is a non-colonizing bacterium, a sys-
tem allowing the bacterium to be preloaded, such as with
NICE system, with antigen before in vivo applications
(vaccine development, for example) are highly desirable.
Note that recombinant L. lactis provide a possible means
for targeting L1 protein to humans. However, the use of
genetically modified microorganisms raises legitimate
concerns about their survival and propagation in the envi-
ronment and about the dissemination of antibiotic selec-
tion markers (such plasmids used in this study) or other
genetic modification to other microorganisms. Thus,
before recombinant bacteria could be applicable to
humans a biologic containment of recombinant microor-
ganisms is necessary [33].
In conclusion, this study demonstrates the potential of the
use of recombinant LAB for the production of HPV-16
VLPs and suggests the development of a new mucosal pro-
phylactic HPV-16 vaccine.
Methods
Bacterial strains and plasmids used
The bacterial strains and plasmids used in this work are
listed in Table 1. Lactococcus lactis strains were grown in
M17 medium (Difco) supplemented with 0.5% glucose
(GM17) at 30°C without agitation. Escherichia coli was
grown in Luria-Bertani at 37°C with vigorous agitation.
Plasmid constructions were first established in E. coli and
then transferred to L. lactis by electrotransformation [24].
Plasmids were selected by addition of antibiotics as fol-
lows: for L. lactis, chloramphenicol (10 μg/ml); for E. coli,
ampicillin (100 μg/ml) and chloramphenicol (10 μg/ml).
Isolation of plasmid DNA was performed by using a Mini-
L. lactis-derived VLPs display conformational epitopes Figure 4
L. lactis-derived VLPs display conformational 
epitopes. ELISA plates were coated with total protein cell 
extracts (diluted in PBS pH 7.0) obtained from either L. lactis 
strain and assayed with a conformational anti-HPV16 L1 anti-
body. The data are the means of two independent experi-
ments. Bars represent the means ± standard deviations. 
Statistically significant differences (P < 0.05) obtained with 
JMP software are denoted by an asterisk (*) between recom-
binant L. lactis strains and control L. lactis (pGK-) strain or by 
two asterisks (**) between L. lactis (pCYT:L1) and L. lactis 
(pSEC:L1) strain.
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Scale purification system (QIAGEN S.A.). Lysozyme (10
mg/ml) was added prior to the lysis step and incubated for
30 min (37°C) to prepare the protoplasts. PCR (Cetus
apparatus; Perkin Elmer, Norwalk, CT) was performed
using Vent DNA polymerase (Promega), and DNA
sequences were confirmed by sequencing (MWG-Biotech
AG). Restriction and DNA-modifying enzymes were used
according to the supplier's recommendations.
Cloning of L1 gene from HPV-16 in L. lactis
A 1,606-bp DNA fragment encoding HPV-16 L1 protein
(without ATG start codon) was PCR amplified from the
pcDNA3-L1 plasmid (Kindly provided by Dr. Willem J.G.
Melchers, Table 1) using primers NsiI-L1 HPV16 (5'-GAT-
GCATCA CAACAGGTGACTTTTATTTACATC-3') for the
coding strand and L1 HPV16 (5'-GTTACAG
CTTACGTTTTTTGCGTTTAGCAG-3') for the complemen-
tary strand. The PCR product was cloned into pCR:TOPO
(Invitrogen), resulting in pCR:TOPO:L1. L1 gene was then
purified from NsiI/SpeI-cut pCR:TOPO:L1 and cloned
into purified backbones isolated from NsiII-SpeI-cut
pCYT:E7 and pSEC:E7 resulting in pCYT:L1 and pSEC:L1
(Table 1). In the resulting plasmid pSEC:L1 (Figure 1), L1
gene is fused in frame with a DNA fragment containing
the ribosome binding site and the signal peptide of usp45
(SPUsp45), the gene encoding Usp45, the predominant L.
lactis-secreted protein [24]. In pCYT:L1 (Figure 1), the
fragment encoding SPUsp45 is absent. In both pCYT:L1 and
pSEC:L1, expression of L1 is controlled by the PnisA pro-
moter [26]. These plasmids were introduced into L. lactis
strain carrying the regulatory genes nisR and nisK (Table 1)
[27]. As a negative control, NZ9000 was transformed with
an empty vector (pGK-).
Inducible expression of L1, protein analysis and 
immunoblotting
For the induction of L1 expression from the nisin pro-
moter, strains were grown to an optical density (OD600) =
0.6, followed by induction with 1 ng/ml of nisin (Sigma)
for 1 h. Protein samples were prepared from 2 ml of L. lac-
tis induced cultures. After centrifugation (5 min, 10,000
rpm), the cell pellet and supernatant were treated sepa-
rately. To compare the amounts of secreted and cell-asso-
ciated proteins, both cell and supernatant fractions were
concentrated and sample concentration calculated as fol-
lows: the equivalent of 1 ml of 1 OD600 unit of the sample
(either cell or supernatant) was concentrated in a 100 μl
final volume as described below, and 10 μl was loaded for
SDS-PAGE. Supernatants were filtered on 0.2 μm pore-
size filters (low protein retention; Millisar NML Sartorius)
and treated with 1 mM PMSF and 10 mM DTT, followed
by the addition of 100 μl of TCA (100%) to precipitate
proteins. Samples were incubated for 10 min on ice, and
proteins were recovered from the pellets after centrifuga-
tion at 4°C for 10 min at 13,000 rpm. The resulting pellet
was dissolved in 1/20 volume of 50 mM NaOH. The cell
fraction was obtained by cell lysis in 70 μl of lysis buffer
(25% sucrose, 1 mM EDTA, 50 mM Tris-HCl [pH 8.0],
and 10 mg/ml lysozyme) complemented with 1 mM
PMSF and 10 mM DTT. After 30 min of incubation at
37°C, cells were lysed with 30 μl of 20% SDS. Equal vol-
umes of 2× loading buffer were added to all samples and
10 μl of each sample were analyzed by SDS-polyacryla-
mide (10 and 12%) gel electrophoresis. Western blotting
on PVDF membranes (Millipore) was carried out using an
HPV-16 L1-specific monoclonal antibody (0.25 μg/ml,
CamVir 1, BD Pharmingen). Immunodetection was per-
formed with protein G-horseradish peroxidase conjugate
(Bio-Rad) at a dilution of 1:5000 and an enhanced chemi-
luminescence kit (Dupont-NEN) as recommended by the
suppliers.
Transmission electron microscopy (TEM)
L. lactis strains were induced as described above and fixed
with 2% glutaraldehyde in 0.1 M of sodium cacodylate
buffer (pH 7.2) for 1 hour at room temperature. Samples
were then post-fixed with 1% osmium tetroxide contain-
ing 1.5% potassium cyanoferrate before gradually dehy-
drating in ethanol (30–100%) and embedding in Epon
resin. Thin sections (70 nm) were collected onto 200
Table 1: Bacterial strains and plasmids used.
Strains Genotype Reference
E. coli TG1 supE, hsd, Δ5, thi, Δ(lac-proAB), F'(traD36 proAB-lacZΔM15) [30]
L. lactis MG1363 Wild type, plasmid free [29]
L. lactis NZ9000 MG1363 (nisRK genes into chromosome), plasmid free [27]
Plasmids Replicon Plasmid characteristics; cloned cassettes characteristics Reference
pcDNA3-L1 ColE1 Apr, plasmid containing the HPV-16 L1 sequence [31]
pCR:TOPO ori pUC Apr Invitrogen
pCR:TOPO:L1 ori pUC Apr, plasmid containing HPV-16 L1 sequence without ATG start codon This work
pCYT:E7 pWV01 Cmr; gene, expressed from PnisA encodes E7 [10]
pSEC:E7 pWV01 Cmr; gene, expressed from PnisA encodes SPUsp-E7 precursor [10]
pCYT:L1 pWV01 Cmr; gene, expressed from PnisA encodes native L1 protein This work
pSEC:L1 pWV01 Cmr; the gene expressed from PnisA encodes SPUsp-L1 precursor This workBMC Research Notes 2009, 2:167 http://www.biomedcentral.com/1756-0500/2/167
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mesh copper grids and counterstained with lead citrate
before examination with Zeiss EM902 TEM operated at 80
kV (Carl Zeiss-France, MIMA2 Microscopy Platform,
UR1196, INRA, Jouy en Josas, France). Images were
acquired with a charge-coupled device camera (Megaview
III) and analysed with ITEM Software (Eloïse, France).
HPV-16 VLP ELISA
ELISA analysis was performed as described previously [28]
with some modifications. Briefly, L. lactis-derived VLPs
and L1 protein were recovered as follows: 10 ml of
induced-L. lactis cultures were pelleted and resuspended
in 3 ml of either PBS pH 7.0 (assembled VLPs) or in car-
bonate buffer (50 mM sodium carbonate, 1 mM MgCl2,
0.01 M of dithiothreitol, pH 10.0) (disassembled VLPs).
Cells were then lysed with 0.1 g of acid-washed glass
beads (150–210 μm, Sigma). Cellular debris were elimi-
nated by centrifugation and 200 μl of supernatant con-
taining VLP's or L1 protein were applied on ninety-six well
plates (Nunc Maxisorp) and incubated at 4°C for 8 h.
Plates were washed twice with PBS plus 0.1% Tween-20
and blocked at room temperature for 1 h with 5% non-fat
dry milk in PBS. After plate washing, 100 μl of either an
anti-HPV16 L1 capsid antigen (HP16M-1521-5, Austral
Biologicals) or anti-L1 (BD Pharmigen) diluted 1:50 in
1% non-fat dry milk in PBS were added. After 2 h of incu-
bation at room temperature the plates were washed and
100 μl of a secondary anti-mouse IgG antibody (alkaline-
phosphatase conjugated goat, Sigma-Aldrich, France)
diluted 1:2500 in 1% non-fat dry milk in PBS was added
and the plate incubated 1 h at 4°C. The plates were
washed and the reaction developed by addition of 200 μl
of  p-nitrophenyl phosphate substrate (Sigma-Aldrich,
France) dissolved at 10 mg/ml in sodium carbonate
buffer. The plates were incubated at room temperature
until yellow colour was developed (30–60 min). Finally
the reaction was stopped by the addition of 50 μl of 2 M
NaOH. The absorbance was immediately measured at 405
nm (A405 nm).
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